Literature DB >> 22226254

Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.

W Kenneth Ward1, Jessica R Castle, Joseph El Youssef.   

Abstract

Patients with type 1 diabetes mellitus (T1DM) must make frequent decisions and lifestyle adjustments in order to manage their disorder. Automated treatment would reduce the need for these self-management decisions and reduce the risk for long-term complications. Investigators in the field of closed-loop glycemic control systems are now moving from inpatient to outpatient testing of such systems. As outpatient systems are developed, the element of safety increases in importance. One such concern is the risk for hypoglycemia, due in part to the delayed onset and prolonged action duration of currently available subcutaneous insulin preparations. We found that, as compared to an insulin-only closed-loop system, a system that also delivers glucagon when needed led to substantially less hypoglycemia. Though the capability of glucagon delivery would mandate the need for a second hormone chamber, glucagon in small doses is tolerated very well. People with T1DM often develop hyperglycemia from emotional stress or medical stress. Automated closed-loop systems should be able to detect such changes in insulin sensitivity and adapt insulin delivery accordingly. We recently verified the adaptability of a model-based closed-loop system in which the gain factors that govern a proportional-integral-derivative-like system are adjusted according to frequently measured insulin sensitivity. Automated systems can be tested by physical exercise to increase glucose uptake and insulin sensitivity or by administering corticosteroids to reduce insulin sensitivity. Another source of risk in closed-loop systems is suboptimal performance of amperometric glucose sensors. Inaccuracy can result from calibration error, biofouling, and current drift. We found that concurrent use of more than one sensor typically leads to better sensor accuracy than use of a single sensor. For example, using the average of two sensors substantially reduces the proportion of large sensor errors. The use of more than two allows the use of voting algorithms, which can temporarily exclude a sensor whose signal is outlying. Elements such as the use of glucagon to minimize hypoglycemia, adaptation to changes in insulin sensitivity, and sensor redundancy will likely increase safety during outpatient use of closed-loop glycemic control systems.
© 2011 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22226254      PMCID: PMC3262703          DOI: 10.1177/193229681100500608

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  28 in total

1.  Understanding spontaneous output fluctuations of an amperometric glucose sensor: effect of inhalation anesthesia and use of a nonenzyme containing electrode.

Authors:  W K Ward; M D Wood; J E Troupe
Journal:  ASAIO J       Date:  2000 Sep-Oct       Impact factor: 2.872

2.  Automation control of blood sugar a servomechanism for glucose monitoring and control.

Authors:  A H KADISH
Journal:  Trans Am Soc Artif Intern Organs       Date:  1963

3.  An implantable subcutaneous glucose sensor array in ketosis-prone rats: closed loop glycemic control.

Authors:  W Kenneth Ward; Michael D Wood; Heather M Casey; Matthew J Quinn; Isaac F Federiuk
Journal:  Artif Organs       Date:  2005-02       Impact factor: 3.094

4.  A novel insulin delivery algorithm in rats with type 1 diabetes: the fading memory proportional-derivative method.

Authors:  Bala Gopakumaran; Heather M Duman; Douglas P Overholser; Isaac F Federiuk; Matthew J Quinn; Michael D Wood; W Kenneth Ward
Journal:  Artif Organs       Date:  2005-08       Impact factor: 3.094

5.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

Authors:  R N Bergman; L S Phillips; C Cobelli
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

6.  Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.

Authors:  Gregory Holmes; Lawrence Galitz; Peter Hu; William Lyness
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

Review 7.  Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment.

Authors:  Isaac F Federiuk; Heather M Casey; Matthew J Quinn; Michael D Wood; W Kenneth Ward
Journal:  Comp Med       Date:  2004-06       Impact factor: 0.982

8.  Quantitative analysis of glycogen repletion by nuclear magnetic resonance spectroscopy in the conscious rat.

Authors:  G I Shulman; L Rossetti; D L Rothman; J B Blair; D Smith
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

9.  [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin.

Authors:  D C Howey; R R Bowsher; R L Brunelle; J R Woodworth
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

10.  Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting.

Authors:  P J Boyle; S D Shah; P E Cryer
Journal:  Am J Physiol       Date:  1989-05
View more
  15 in total

1.  Pharmacokinetics modeling of exogenous glucagon in type 1 diabetes mellitus patients.

Authors:  Dayu Lv; Marc D Breton; Leon S Farhy
Journal:  Diabetes Technol Ther       Date:  2013-08-26       Impact factor: 6.118

2.  Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience.

Authors:  Signe Schmidt; Dimitri Boiroux; Anne Katrine Duun-Henriksen; Laurits Frøssing; Ole Skyggebjerg; John Bagterp Jørgensen; Niels Kjølstad Poulsen; Henrik Madsen; Sten Madsbad; Kirsten Nørgaard
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

3.  Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.

Authors:  P A Bakhtiani; J El Youssef; A K Duell; D L Branigan; P G Jacobs; M R Lasarev; J R Castle; W K Ward
Journal:  J Diabetes Complications       Date:  2014-09-16       Impact factor: 2.852

Review 4.  Physical activity and type 1 diabetes: time for a rewire?

Authors:  Sheri R Colberg; Remmert Laan; Eyal Dassau; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2015-01-06

5.  Identification of Main Factors Explaining Glucose Dynamics During and Immediately After Moderate Exercise in Patients With Type 1 Diabetes.

Authors:  Najib Ben Brahim; Jerome Place; Eric Renard; Marc D Breton
Journal:  J Diabetes Sci Technol       Date:  2015-10-18

6.  Multivariable adaptive closed-loop control of an artificial pancreas without meal and activity announcement.

Authors:  Kamuran Turksoy; Elif Seyma Bayrak; Lauretta Quinn; Elizabeth Littlejohn; Ali Cinar
Journal:  Diabetes Technol Ther       Date:  2013-04-01       Impact factor: 6.118

7.  Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels.

Authors:  Joseph El Youssef; Jessica R Castle; Parkash A Bakhtiani; Ahmad Haidar; Deborah L Branigan; Matthew Breen; W Kenneth Ward
Journal:  Diabetes Care       Date:  2014-08-19       Impact factor: 19.112

Review 8.  Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2017-06       Impact factor: 6.118

Review 9.  A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy.

Authors:  P A Bakhtiani; L M Zhao; J El Youssef; J R Castle; W K Ward
Journal:  Diabetes Obes Metab       Date:  2013-04-21       Impact factor: 6.577

10.  An integrated multivariable artificial pancreas control system.

Authors:  Kamuran Turksoy; Lauretta T Quinn; Elizabeth Littlejohn; Ali Cinar
Journal:  J Diabetes Sci Technol       Date:  2014-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.